Comprehensive geriatric assessments will play an increasingly important role in identifying patient frailty and personalizing geriatric oncology treatment, according to recently published reviews.
Extending the platinum-free interval following disease progression in ovarian cancer with a non-platinum agent does not improve outcomes over the standard practice of using a platinum-based chemotherapy, according to a prospective trial.
A large database study found that most patients with stage I endometrioid epithelial ovarian cancer or ovarian clear cell cancer do not have better survival outcomes when treated with adjuvant chemotherapy.
The relative importance of common chemotherapy side effects has shifted substantially over the last few decades, according to a new study. In general, psychosocial effects have become more important while physical effects seem less significant to patients than in the past.
Weekly dose-dense chemotherapy can be delivered successfully and with lower toxicity than standard 3-weekly regimens, but it does not improve progression-free survival among patients with epithelial ovarian cancer, according to a large new study presented at the ESMO.
The FDA approved olaparib as maintenance therapy for adult patients with recurrent ovarian cancer. The agent is also now approved in tablet form.
Two studies on Lynch syndrome highlight cancer screening and surveillance opportunities.
Olaparib tablet maintenance therapy provided a significant improvement in progression-free survival over placebo in patients with relapsed, platinum-sensitive ovarian cancer with a BRCA1/2 mutation.
A new study that used prospective data provides estimates of cancer risk based on BRCA1/2 mutation status and shows the potential role of family history and the location of the mutation in assessing risk.
Niraparib is the most effective but most costly of the currently FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.